Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 17 studies | 35% ± 13% | |
intestine | 9 studies | 35% ± 19% | |
brain | 9 studies | 27% ± 10% | |
kidney | 9 studies | 36% ± 14% | |
peripheral blood | 7 studies | 22% ± 9% | |
eye | 6 studies | 26% ± 11% | |
uterus | 6 studies | 41% ± 12% | |
liver | 5 studies | 32% ± 11% | |
lymph node | 4 studies | 39% ± 31% | |
breast | 4 studies | 40% ± 11% | |
pancreas | 3 studies | 31% ± 8% | |
placenta | 3 studies | 22% ± 3% | |
ovary | 3 studies | 31% ± 13% | |
adipose | 3 studies | 34% ± 5% | |
adrenal gland | 3 studies | 33% ± 9% | |
esophagus | 3 studies | 35% ± 18% | |
skin | 3 studies | 31% ± 16% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
adrenal gland | 100% | 44595.74 | 258 / 258 | 97% | 606.20 | 223 / 230 |
prostate | 98% | 40602.18 | 241 / 245 | 98% | 558.18 | 493 / 502 |
breast | 100% | 53135.78 | 457 / 459 | 96% | 741.56 | 1068 / 1118 |
brain | 93% | 20342.81 | 2450 / 2642 | 100% | 1015.03 | 703 / 705 |
bladder | 100% | 56523.29 | 21 / 21 | 91% | 314.71 | 457 / 504 |
lung | 98% | 42492.88 | 566 / 578 | 90% | 367.01 | 1039 / 1155 |
liver | 89% | 24684.40 | 202 / 226 | 97% | 564.63 | 392 / 406 |
stomach | 90% | 40970.18 | 322 / 359 | 90% | 344.11 | 257 / 286 |
intestine | 87% | 49321.67 | 844 / 966 | 91% | 307.38 | 481 / 527 |
uterus | 98% | 44543.10 | 167 / 170 | 79% | 309.77 | 364 / 459 |
thymus | 88% | 20288.88 | 575 / 653 | 88% | 332.44 | 534 / 605 |
kidney | 84% | 16955.07 | 75 / 89 | 92% | 897.06 | 829 / 901 |
esophagus | 83% | 47954.51 | 1196 / 1445 | 91% | 359.82 | 166 / 183 |
ovary | 98% | 47170.79 | 177 / 180 | 69% | 169.99 | 295 / 430 |
skin | 74% | 28572.83 | 1346 / 1809 | 72% | 202.23 | 342 / 472 |
pancreas | 27% | 3841.07 | 88 / 328 | 96% | 409.36 | 170 / 178 |
ureter | 0% | 0 | 0 / 0 | 100% | 111.06 | 1 / 1 |
adipose | 100% | 62462.51 | 1203 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 125570.05 | 1332 / 1335 | 0% | 0 | 0 / 0 |
heart | 88% | 21633.38 | 761 / 861 | 0% | 0 | 0 / 0 |
muscle | 78% | 22928.10 | 630 / 803 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 69% | 154.35 | 31 / 45 |
spleen | 66% | 11084.77 | 158 / 241 | 0% | 0 | 0 / 0 |
peripheral blood | 37% | 15754.43 | 348 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 20% | 27.80 | 16 / 80 |
lymph node | 0% | 0 | 0 / 0 | 7% | 9.37 | 2 / 29 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0001525 | Biological process | angiogenesis |
GO_0045786 | Biological process | negative regulation of cell cycle |
GO_0045766 | Biological process | positive regulation of angiogenesis |
GO_0007165 | Biological process | signal transduction |
GO_0010595 | Biological process | positive regulation of endothelial cell migration |
GO_0006886 | Biological process | intracellular protein transport |
GO_0000281 | Biological process | mitotic cytokinesis |
GO_0007155 | Biological process | cell adhesion |
GO_0061154 | Biological process | endothelial tube morphogenesis |
GO_0030154 | Biological process | cell differentiation |
GO_0030334 | Biological process | regulation of cell migration |
GO_0008333 | Biological process | endosome to lysosome transport |
GO_0007015 | Biological process | actin filament organization |
GO_0006915 | Biological process | apoptotic process |
GO_0007266 | Biological process | Rho protein signal transduction |
GO_0030336 | Biological process | negative regulation of cell migration |
GO_0071479 | Biological process | cellular response to ionizing radiation |
GO_0099159 | Biological process | regulation of modification of postsynaptic structure |
GO_0043065 | Biological process | positive regulation of apoptotic process |
GO_0070301 | Biological process | cellular response to hydrogen peroxide |
GO_0031902 | Cellular component | late endosome membrane |
GO_0098685 | Cellular component | Schaffer collateral - CA1 synapse |
GO_0005886 | Cellular component | plasma membrane |
GO_0005769 | Cellular component | early endosome |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005925 | Cellular component | focal adhesion |
GO_0005829 | Cellular component | cytosol |
GO_0010008 | Cellular component | endosome membrane |
GO_0032154 | Cellular component | cleavage furrow |
GO_0005634 | Cellular component | nucleus |
GO_0019003 | Molecular function | GDP binding |
GO_0005525 | Molecular function | GTP binding |
GO_0005515 | Molecular function | protein binding |
GO_0003924 | Molecular function | GTPase activity |
Gene name | RHOB |
Protein name | Rho-related GTP-binding protein RhoB (Rho cDNA clone 6) (h6) |
Synonyms | ARHB ARH6 |
Description | FUNCTION: Mediates apoptosis in neoplastically transformed cells after DNA damage. Not essential for development but affects cell adhesion and growth factor signaling in transformed cells. Plays a negative role in tumorigenesis as deletion causes tumor formation. Involved in intracellular protein trafficking of a number of proteins. Targets PKN1 to endosomes and is involved in trafficking of the EGF receptor from late endosomes to lysosomes. Also required for stability and nuclear trafficking of AKT1/AKT which promotes endothelial cell survival during vascular development. Serves as a microtubule-dependent signal that is required for the myosin contractile ring formation during cell cycle cytokinesis. Required for genotoxic stress-induced cell death in breast cancer cells. . |
Accessions | ENST00000272233.6 P62745 |